<div class="container">Avalon Biomedical (Management) Limited is a pioneering life sciences company driving biomedical innovation through cutting-edge research, technology integration, and cross-disciplinary collaboration. As part of our strategic expansion, we are advancing AI-driven healthcare solutions in drug discovery, medical imaging, equipment maintenance, and traditional Chinese medicine—prioritizing data security, regulatory compliance, and assistive applications for healthcare professionals. Our AI solutions enhance clinical decision-making, optimize hospital operations, and transform medical education. Through strong partnerships with academia, industry, and healthcare institutions, we are accelerating intelligent, precision-driven healthcare development while shaping a smarter, more connected biomedical ecosystem.<br /><br /></div><div style="padding-bottom: 100px;"> </div>

Avalon Biomedical (Management) Limited

<div class="container">Emerging Viral Diagnostics (Hong Kong) Limited (EVDL) is a Hong Kong-based MedTech company composed of a team of experienced interdisciplinary experts. By integrating academic, industrial, and research expertise, the company successfully transformed the "Fully Automated Multiplex Diagnostic System" from an unmet medical need into an innovative and practical diagnostic solution. In 2024, this system was recommended by the World Health Organization as an innovative health technology suitable for low-resource settings and was softly launched to the market. EVDL is committed to becoming a global leader in the diagnostic industry, continuously pushing Diagnosis beyond Boundaries!</div><div style="padding-bottom: 100px;"> </div>

Emerging Viral Diagnostics (HK) Limited

<div class="container">Eieling Technology is dedicated to advancing liver health through the seamless integration of cutting-edge technology and clinical medicine. Our pipelines are committed to providing healthcare providers with accurate, efficient, and reliable diagnostic solutions for liver disease managements.<br><br>Focusing on the core needs of liver disease prevention, diagnosis, and treatment, Eieling offers a range of advanced products that address every stage of liver care. Our comprehensive, multi-dimensional diagnostic and data management systems provide clinicians with powerful tools for early detection, real-time assessment, and long-term disease management.
</div><div style="padding-bottom: 100px;"> </div>

Eieling Technology Limited

雙蟻藥業成立於1971年，位於藥材資源豐富的壯藥之都—來賓市。2012年至今連續多次獲得國家高新技術企業認定，連續五年登上中國中央電視台宣傳企業，廣西著名製藥企業，廣西技術創新示範企業，專精特新企業和廣西瞪羚企業。本公司擁有顆粒劑、膠囊劑、錠劑、糖漿劑等7大劑型及「藥材多三味治感冒雙蟻複方更有效」的複方感冒靈顆粒等42個產品批文。作為複方感冒靈顆粒開拓者，公司聚焦該單品10年，現單品銷售出廠價2億元。兩個生產基地佔地9萬多平方米，生產車間3萬平方米，倉庫3.6萬平方米，新的生產基地年提取能力超過一萬噸中藥材，公司年生產能力可達15-20億元。<br><br>截至目前，本公司擁有登記作品7個，註冊商標46件，14項自主智慧財產權，其中4項發明專利，9項實用新型專利，1項外觀專利，在申請1項實用新型專利。<br><br>本公司榮獲「全國高新技術企業認定」、「中國品質信用3A+企業」、「全國工人先鋒號」、自治區「專精特新」中小企業、自治區「技術創新示範企業」、「中國知名品牌」等榮譽稱號。<br><br>雙蟻藥業始於1971年<br>世界壯醫企業引領者<br>複方感冒靈顆粒開拓者<br>小螞蟻，有力量！小螞蟻，大夢想！<br><br>聯絡方式：0772-4234999<br><br>聯絡地址：廣西賓客市鳳翔路11號<br><br>官網：<a href="https://www.shyipharma.com/" target="_blank">www.shyipharma.com</a>

Guangxi Shuangyi Pharmaceutical Co., Ltd

<div class="container">HIHUB.TECH@Health Innova HUB is a Leading Brazilian HUB Focused on Developing and promoting businesses among Healthcare Innovation Leaders.<br /><br />Our clients are among the most successful business Healthcare Leaders, in Brazil, located all over the country and abroad.<br /><br />We have 4 Pillars: Academy, Members, Challenges and Experiences and we promote exclusive events to promote networking and business relations among our attendees.<br /><br />We have already promoted 4 Healthcare Innovation Missions to Silicon Valley, One to Canada and One to China, in 2019.<br /><br />This year, 2025, we are returning to China with a Delegation, of 16 CEOs and Healthcare Innovation Leaders, looking for solutions to bring to Brazil.<br /><br />Website: <a style="color: #41aead;" href="https://hihub.tech" target="_blank" rel="noopener">https://hihub.tech</a></div><div style="padding-bottom: 100px;"> </div>

Health Innova HUB (HIHUB)

<div class="container">Founded in 2013, Hong Kong Molecular Pathology Diagnostic Centre (HKMPDC) is the first professional medical laboratory that specializes in molecular testing of the Hybribio Group(SHE:300639).HKMPDC is the first HOKLAS ISO 15189:2012 accredited laboratory for Molecular Oncology Testing in Hong Kong. An extensive list of molecular tests of the best quality is offered, ranging from infectious diseases, clinical oncology, haematopathology, to various genetic disorders. It is also the first unique ISO certified hereditary cancer testing centre in Hong Kong.<div style="padding-bottom: 100px;"> </div></div>

Hong Kong Molecular Pathology Diagnostic Centre Limited

<div class="container">Jiangsu Zhizi Nano Technology Co., Ltd. is an innovative technology company focused on delivering intelligent infection control solutions for the healthcare sector through optical and artificial intelligence technologies. Headquartered in Yangzhou, Jiangsu Province, the company possesses full in-house capabilities for R&amp;D, productization, and clinical deployment. Zhizi Nano focuses on infection prevention in ICU and perioperative settings and has established collaborations with multiple tertiary hospitals in Jiangsu, as well as research partnerships with leading universities such as Huazhong University of Science and Technology.</div><div style="padding-bottom: 100px;"> </div>

Jiangsu ZhiziNano Tech Co.,Ltd

<div class="container">Merck is a leading science and technology company with a rich history dating back to 1668. With approximately 63,000 employees worldwide, Merck operates in three main sectors: Healthcare, Life Science and Electronics. The company is dedicated to improving the quality of life through innovative solutions in pharmaceuticals, biotechnology and high-tech materials. Merck Healthcare aims to improve patient outcomes through advanced therapies in areas such as oncology, neurology and immunology. Emphasizing patient-centric approaches, Merck collaborates with healthcare professionals to ensure accessibility and effectiveness of the products, and is committed to making a positive impact on society.</div><div style="padding-bottom: 100px;"> </div>

Merck Pharmaceutical (HK) Limited

<div class="container">Nano and Advanced Materials Institute (NAMI) is designated by the Innovation and Technology Commission of HKSAR Government as a Research and Development Center for nanotechnology and advanced materials. NAMI undertakes and provides support for market-driven research in nanotechnology and advanced materials, and strives for commercialization of the technologies to benefit the industry and society at large, as well as new industrialization to promote economic growth and sustainability of Hong Kong.<br /><br />As a Materials Expert, NAMI has a strong portfolio of innovative technologies to support and collaborate with industry, offering frontier-applied research on advanced materials and technology transfer for commercialization success.<br /><br />Website: <a style="color: #41aead;" href="https://www.nami.org.hk" target="_blank" rel="noopener">https://www.nami.org.hk</a></div><div style="padding-bottom: 100px;"> </div>

Nano and Advanced Materials Institute Limited

<div class="container">From medical clinics to community pharmacies, Scribo revolutionizes operations of diverse primary healthcare practices and elevate patient experiences with our intelligent and data-driven SaaS solution. With expertise in drug utilization data management backed by our co-founding team of pharmacists, we also offer solutions for the pharmaceutical industry in digitizing operations of drug access programs they sponsor, fostering seamless collaborations with healthcare providers.</div><div style="padding-bottom: 100px;"> </div>

Scribo Limited

<div class="container">Under the guidance of the Science and Technology Commission of Shanghai Municipality, Shanghai Center of Biomedicine Development has organized the Shanghai Biomedical Innovation Pavilion. The pavilion converges over 20 innovative pharmaceutical companies, cutting-edge medical device enterprises, R&amp;D service providers, and consulting firms. Committed to fostering industrial collaboration and facilitating technological transfer, Shanghai and Hong Kong aim to jointly explore global markets and usher in a new chapter of innovation and development in the biomedical field.</div><div style="padding-bottom: 100px;"> </div>

Shanghai Center of Biomedicine Development

<div class="container">The Shenzhen Pingshan Biomedical Industry Accelerator Park is located within the National Bio-industry Base of Pingshan High-tech Zone. It covers an area of approximately 106,000 square meters and has a total construction area of about 691,200 square meters. The park consists of 14 buildings, including 115,300 square meters of research and development facilities, 283,100 square meters of production plants, and approximately 87,000 square meters of multi-functional supporting facilities such as apartments and commercial amenities. The park aims to create an integrated biomedical industrial park that combines research and development, incubation, production, and multi-functional support, integrating urban functions with industrial elements.</div><div style="padding-bottom: 100px;"> </div>

Shenzhen Grandbay Biomedical Development Consulting Co. Ltd.

Xiamen Municipal Bureau of Science and Technology

<div class="container">The Incinta Fertility Center, located near the Pacific Ocean in Torrance, California, occupies over 20,000 square feet and exemplifies the highestquality of assisted reproduction technologies (ART).<br /><br />We carefully considered every detail from site selection to completedconstruction, made possible by a team of exceptionally skilled designers and engineers.</div><div style="padding-bottom: 100px;"> </div>

Beijing Yunshida Medical Treatment Investment Management Co., ltd

<div class="container">Founded in 2017, Zhaoke Ophthalmology (SEHK: 6622) is a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs in the world. The company was listed in the Main Board of the Hong Kong Stock Exchange on 29 April 2021.
Zhaoke Ophthalmology has a comprehensive drug portfolio of innovative and generic treatments covering six major eye diseases across both the front and back of the eye. Many of the drugs are being produced in its state-of-the-art and fully functional development and production facility in Nansha, Guangzhou.<br><br>Zhaoke Ophthalmology is focusing on advancing towards the goal of product commercialisation,and achieve the objective of improving visual health in China through scientific research as soon as possible.<br><br>Through its ambitious growth strategy, including partnering with domestic and international pharmaceutical companies, Zhaoke Ophthalmology’s goal is to become a leader in ophthalmology in the world.<br /><br />Website: <a style="color: #41aead;" href="https://www.zkoph.com/" target="_blank" rel="noopener">www.zkoph.com</a></div>
</div><div style="padding-bottom: 100px;"> </div>

Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited

<div class="container">WhiteOak’s One-Stop CDMO Services offer a seamless experience with a single partner, combining our expertise in development, manufacturing, contract testing, and cutting-edge technologies from pre-clinical to commercial stages. We accelerate our clients' milestones and breakthroughs by leveraging over 10 years of global success in our proprietary QTsome™ delivery platform. Our services include the development and translation of nucleic acid drugs, mRNA vaccines, oligonucleotide drugs, and high-end complex injectables, as well as bioprocessing of RNA products, including IVT and LNP manufacturing under cGMP standards. Aligned with our global supply network, we help fast-track our clients’ programs.<br /><br />母公司官網連結: <a style="color: #41aead;" href="http://www.zhejianghaichang.com" target="_blank" rel="noopener">http://www.zhejianghaichang.com</a><br>公司官網連結: <a style="color: #41aead;" href="http://whiteoakpharma.com" target="_blank" rel="noopener">http://whiteoakpharma.com</a></div><div style="padding-bottom: 100px;"> </div>

Zhejiang Haichang Biomedical Technology Co., Ltd

<div class="container">ZSHK Laboratories Limited is a biopharmaceutical pre-clinical research and development service company mainly engaged in pre-clinical research and evaluation services for drugs and medical devices. As a one-stop evaluation and research service platform, it provides services including pharmacology, pharmacodynamics, pharmacokinetics, toxicology and other safety-related studies for pharmaceutical developers and researchers worldwide.</div><div style="padding-bottom: 100px;"> </div>

ZSHK Laboratories Limited

Exhibitor

<div class="container">The FHKI Group 33 (Biotechnology and Healthcare Council) is established in 2024 to further propel the growth of biotechnology and healthcare sectors alongside Hong Kong's broader new industrialisation and I&amp;T ambitions. The Council encompasses a diverse array of enterprises, including those in biotechnology, biomedical, traditional Chinese medicine, health supplements, and health devices. Its primary objectives are to reflect Hong Kong's evolving industrial landscape, foster sectoral growth, and enhance service delivery to pertinent businesses.</div><div style="padding-bottom: 100px;"> </div>

The FHKI Group 33 (Biotechnology and Healthcare Council)

<div class="container">Hong Kong Biotechnology Organization (HKBIO) is an independent nonprofit dedicated to advancing biotechnology and life sciences. Committed to promoting best practices and raising industry awareness, HKBIO supports a diverse community, including students, researchers, entrepreneurs, and public and private sector representatives. Founded by pioneering scientists with deep expertise in life sciences, research, development, engineering, and business, HKBIO works to build a global platform for Hong Kong's biotech sector, foster international collaboration, and offer technical advice to government bodies, healthcare institutions, and the general public. HKBIO is a catalyst for innovation and
scientific excellence.</div><div style="padding-bottom: 100px;"> </div>

Hong Kong Biotechnology Organisation

<div class="container">The Hong Kong College of Health Service Executives (HKCHSE) was established in 2005, in recognition of the emergence of health service management as a specialty in its own right and to promote the professional advancement of health service management. Its predecessor was the Hong Kong Society of Health Service Executives, which was dissolved soon after the establishment of the College.<br /><br />The College has been providing a one-year Dual Fellowship Program in conjunction with the Australasian College of Health Service Management for the past twenty years. The Program targets those healthcare professionals and administrators who have the aspirations in pursuing a career in healthcare administration and management. More than two hundred candidates have successfully completed the program and become fellows of the two Colleges, with several of them taking up senior leadership positions in the healthcare sector of Hong Kong and Macau.</div><div style="padding-bottom: 100px;"> </div>

Hong Kong College of Health Service Executives

<div class="container">The Hong Kong Council of Social Service (HKCSS), a statutory body established since 1947, is committed to building an impact-oriented, collaborative social service sector, and co-creating a better society with its over 520 Agency Members, who provides high-quality social services across Hong Kong. Its Innovation and Technology for Ageing department (ITA) strives to contribute towards a better and more respectable life by gerontechnology. It aims to enhance the development of gerontechnology in Hong Kong by encouraging more application, engaging sectoral dialogues and collaboration in driving related policy development, as well as increasing public awareness and participation.</div><br /><br /><div style="padding-bottom: 100px;"> </div>

Hong Kong Council of Social Service

<div class="container">HK Bio-Med Innotech Association is dedicated to establishing an innovative and international biomedical technology hub in Hong Kong. We actively introduce outstanding biomedical innovation technology projects and industries from overseas and provide comprehensive assistance, including formulating industrialization and commercial development plans, fundraising and listing, corporate governance and auditing, R&D technology, patent protection, policy regulations, clinical trial design and planning, to enter the domestic and Asian markets. Through various projects (exchange activities, talent training, policy recommendations, industry docking, etc.), we promote communication, exchange, and cooperation among the biomedical innovation technology industry, research institutions, investment industry, and government organizations in innovative research and development, industrialization, regulatory policy coordination, investment, and financing.</div><div style="padding-bottom: 100px;"> </div>

HK Bio-Med Innotech Association

<div class="container">HKPC is a multi-disciplinary organisation established by statute in 1967, to promote productivity excellence through relentless drive of world-class advanced technologies and innovative service offerings to support Hong Kong enterprises. Being a key enabler of Industry 4.0 and Enterprise 4.0, HKPC strives to facilitate new industrialisation in Hong Kong, as well as bolstering Hong Kong to be an international innovation and technology hub and a smart city. HKPC’s Green Living and Innovation Division has established the “HealthTech and Chinese Medicine Team”, actively supporting the related development of technological innovation in healthcare.
<br />
  <br />
  Website: <a style="color: #41aead;" href="https://www.hkpc.org/en" target="_blank" rel="noopener">https://www.hkpc.org/en</a></div>

<div style="padding-bottom: 100px;"> </div>

Hong Kong Productivity Council

<div class="container">Incorporated in 1907 with limited liability, The Law Society of Hong Kong (“the Law Society”) is the professional association for solicitors in Hong Kong.<br /><br />As a statutory independent self-regulatory professional body, the Law Society ensures compliance by solicitors with relevant laws and regulations, promotes good standards of practice and provides services to its members. The Law Society also has a certificating role in the solicitors’ admission procedure. It is empowered by law to issue annual practising certificates to Hong Kong solicitors and registration certificates to foreign lawyers and foreign law firms in Hong Kong.<br /><br />As an international legal service centre, Hong Kong is well supported by a strong legal profession equipped with top quality professional expertise in a wide range of legal services to meet the diversified needs of clients.<br /><br />As of the end of February 2025, the Law Society had 13,239 members, out of whom 11,481 had a current practising certificate to practise as a Hong Kong solicitor. There were also 1,578 foreign lawyers qualified primarily from 31 jurisdictions.<br /><br /><strong>Contact Information</strong><br /><br />Address: 3/F Wing On House, 71 Des Voeux Road Central, Hong Kong<br /><br />Tel: 852 2846 0500<br /><br />Fax: 852 2845 0387<br /><br />E-mail: <a href="mailto:adceag@hklawsoc.org.hk">adceag@hklawsoc.org.hk</a><br /><br />Website: <a style="color: #41aead;" href="https://www.hklawsoc.org.hk" target="_blank" rel="noopener">www.hklawsoc.org.hk</a></div><br /><br /><div style="padding-bottom: 100px;"> </div>

Law Society of Hong Kong

<div class="container">Founded in 1968, the Hong Kong Association of the Pharmaceutical Industry (HKAPI) represents 36 Research and Development pharmaceutical company members, including the world’s top 20. Our member companies provide over 70% of the prescription medicines in HK.<br /><br />HKAPI embraces its mission to ensure expeditious access to innovative healthcare solutions for people in HK and Macao with high ethical standards.<br /><br />HKAPI is a platform for the industry working with the government, academics, patients groups and communities, aiming to improve the overall well-being of HK people by making recommendations on improving the accessibility and affordability of medicines for patients in need as well as healthcare policies and regulations.</div><br /><br /><div style="padding-bottom: 100px;"> </div>

The Hong Kong Association of the Pharmaceutical Industry 

<div class="container">Founded in 2003, the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA) is a professional organization dedicated to representing the MedTech industry in Hong Kong.<br /><br />We serve as a platform for the MedTech ecosystem. We facilitate connections among policy makers, industry stakeholders, academia, research and development entities.<br /><br />Our membership comprises innovators, manufacturers, importers, exporters, logistics providers, regulatory bodies, legal professionals, and others involved in the field.<br /><br />As a nonprofit organization, HKMHDIA is committed to promoting the well-being of Hong Kong and is recognized as a caring company.</div><br /><br /><div style="padding-bottom: 100px;"> </div>

Hong Kong Medical and Healthcare Device Industries Association 

Affiliate Partner

About the Summit

Honorary Advisors (2025)

Steering Committee (2025)

ASGH Brochure

Join ASGH Community

Previous Summit

Contact Us

ABOUT ASGH

Registration

Speakers

Programme